Orthofix reports Q4 2022 results; SeaSpine merger closed Jan 5; combined 2023 guidance $743-753M

Orthofix Medical Inc.

Orthofix stand-alone Q4 net sales $122.2M (-2% reported, flat constant currency); net loss $7.1M vs $32.8M loss prior year.
SeaSpine stand-alone Q4 net sales $63.4M (+14% YoY); net loss $19.0M vs $18.8M loss prior year.
Combined company expects Q1 2023 net sales $166-170M and full-year 2023 net sales $743-753M.
Merger of Orthofix and SeaSpine completed January 5, 2023; results do not include merger accounting adjustments.
Orthofix borrowed $45M under credit facility in Jan/Mar 2023 to fund merger expenses and working capital.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Orthofix Medical Inc. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 6, 2023, Orthofix Medical Inc. (the “Company”) issued a news release announcing, among other things, its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

Orthofix Medical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006239

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.